Complex trait diseases such as autoimmunity are determined by poorly understood genetic and environmental interactions. The T cell mediated autoimmune diseases Multiple Sclerosis (MS) and Type 1 diabetes (T1D) exemplify this problem, where identical twins of Northern European descent are discordant ~60-70% of the time despite displaying an ~150-300 times higher risk than the general population prevalence of ~0.1% and ~0.4%, respectively (1;2).
Geneticenvironmental interactions have been established between disease-associated MHC haplotypes and specific pathogen peptides that mimic disease self antigens (3;4). The prevalence of MS and T1D change along north -south gradients, implicating ultra-violet light exposure and production of Vitamin D3 in the skin (5-7), a hormone known to negatively regulate T cell function, the MS animal model Experimental Autoimmune Encephalomyelitis (EAE) and spontaneous autoimmune diabetes in the Non-Obese Diabetic (NOD) mouse (5;8-11) . However, molecular mechanisms for genetic -environmental interactions are poorly understood.
Salvage of glucosamine by the hexosamine pathway to UDP-GlcNAc is reported to suppress T cell function and EAE in mice by an unknown mechanism (12;13) . De novo biosynthesis of UDP-GlcNAc by the hexosamine pathway utilizes glucose, acetyl-CoA, glutamine and UTP ( Fig. 1) , key allosteric regulators of basic metabolism, suggesting regulation of UDP-GlcNAc supply is integrated with down-stream pathways requiring this sugar-nucleotide. In this regard, the Golgi pathway to β1,6GlcNAc-branched N-glycans is sensitive to cellular UDP-GlcNAc levels (14) , and play a role in T cell function (15) . Mice deficient in Golgi UDP-GlcNAc:β1,6N-acetylglucosaminyltransferase V (Mgat5) display enhanced delayed-type hypersensitivity, spontaneous kidney autoimmunity after 1 year of age, and increased susceptibility to EAE (15) .
Most transmembrane receptors on mammalian cells are modified by N-glycosylation en route to the cell surface. The Nacetylglucosaminyltransferases I, II, IV and V, encoded by the genes Mgat1, 2, 4a/b and Mgat5, act sequentially to transfer N-acetyl-Dglucosamine (GlcNAc) from UDP-GlcNAc to Nglycan intermediates in the medial Golgi, producing mono, bi-, tri-and tetra-antennary Nglycans, respectively (16;17) (Fig. 1 ). (Fig. 1) . Branching, and particularly the β1,6GlcNAc-branched tetra-antennary N-glycans are subsaturating, as Mgat1, 2, 4 and 5 display decreasing affinities for UDP-GlcNAc, and enzyme concentrations also decline across the pathway ( Fig. 1) (17) .
Galectins, a family of Nacetyllactosamine-binding animal lectins, bind cell surface glycoproteins and form a molecular lattice that negatively regulates lateral movement and endocytic loss of surface receptors and transporters (15;18-21) . Galectins bind to Nglycans on surface glycoproteins with affinities proportional to GlcNAc-branching ( Fig. 1 ) (15;18;19) . β1,6GlcNAc-branched N-glycans are preferentially extended by poly-Nacetyllactosamine (ie (Galβ1,4GlcNAcβ1,3-) n ), further increasing avidity for galectins. However, increasing the proportion of tri-antennary structures in Mgat5 deficient cells is sufficient to rescue defects in galectin binding and surface retention of receptors (22) . In addition, the number of N-glycans, an encoded feature of protein sequence (N-X-S/T), contributes to galectin avidity and regulates surface residency of receptors in a selective manner (22) . With increasing hexosamine flux of UDP-GlcNAc through the Golgi to N-glycan GlcNAc branching, surface galectin binding and retention of glycoproteins with high N-glycan multiplicity (EGFR, IGFR, PDGFR, bFGFR) are enhanced before those with lower multiplicity (TGF-β receptor, CTLA-4 and GLUT-4) (22) . This provides a mechanism for metabolic regulation of cellular transitions between growth (ie EGFR, IGFR, PDGFR, bFGFR) and arrest signaling (ie TGF-β receptor, CTLA-4 and GLUT-4) (22) .
β1,6GlcNAc-branched N-glycans attached to the T cell receptor enhance binding to galectin-3, limiting TCR clustering at the immune synapse and increasing agonist thresholds for TCR signaling (15;22;23) . After TCR activation, endocytosis rates are increased and Src-family kinases and PI3K/Erk stimulate hexosamine flux and Golgi processing to β1,6GlcNAc-branched Nglycans, thereby enhancing surface retention of the growth suppressor CTLA-4 (22) . Therefore, β1,6GlcNAc-branched N-glycans regulate different receptors and at two distinct phases of the T cell response, both serving to suppress T cell activation and autoimmune mechanisms. Here we demonstrate that surface β1,6GlcNAc-branched Nglycans on T cells are regulated by the nutrient environment and metabolite supply to the hexosamine pathway. Hexosamine supplements suppress TCR sensitivity, T H 1 differentiation and autoimmunity by increasing N-glycan GlcNAcbranching in T cells. Our results indicate that genetic and environmental contributions to metabolic homeostasis and Golgi processing regulate N-glycan branching, T cell function and autoimmunity and suggest new avenues for prevention and treatment of autoimmune disease (Fig. 7) .
EXPERIMENTAL PROCEDURES
FACS analysis and In Vitro proliferation assays -PL/J mice were congenic at backcross six from our original 129/Sv Mgat5 -/-mice (24). NOD mice were obtained from Jackson laboratories at 5 weeks of age. Procedures and protocols with mice were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine. Mouse cells were stained with anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CTLA-4 (UC10-4B9), anti-CD28 (37.51) and anti-CD69 (H1.2F3), from eBioscience, Phaseolus vulgaris leukoagglutinating lectin (L-PHA, 4 µg/ml), Lycopersicon esculentum agglutinating lectin (LEA, 20 µg/ml) and 7-Aminoactinomycin D (7-AAD; 1 µg/ml) from Sigma. Purified CD3 + T-cells (R&D Systems) were labeled with 5 µM 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) in PBS for 8 min at room temperature and stimulated with plate bound anti-CD3ε (2C11, eBioscience) in the presence or absence of GlcNAc and/or swainsonine (SW) (Sigma). Jurkat T cells were cultured in either glutamine-free RPMI 1640, 10% FBS, 10mM /20mM glucose or glucose/glutamine-free DMEM base media supplemented with 10% FBS, 1.5mM glucose. The indicated monosaccharides and/or metabolites were added daily except glucose which was added only at time zero and were titrated until a plateau was reached in L-PHA staining or toxicity was observed. The plateau or highest non-toxic dose is shown.
TCR signaling -1x10 6 purified splenic CD3 + Tcells from Mgat5
+/-and Mgat5 -/-mice or from purified T-cell cultures incubated in the presence or absence of GlcNAc (80 mM) and/or swainsonine (0.25 µM) for 72 h were mixed with 5x10 6 polystyrene beads (6 micron, Polysciences) coated at 4 o C overnight with 0.5 µg/ml anti-CD3ε antibody (2C11, eBioscience) and pelleted at 5,000 rpm for 15 s, incubated at 37˚C for the indicated times, and then solubilized with ice-cold 50 mM Tris pH 7.2, 300 mM NaCl, 1.0% Triton X-100, protease inhibitor cocktail (Boehringer Mannheim) and 2 mM Orthovanadate for 20 min. Cell lysates were separated on Nupage10 % BIS-TRIS gels (Invitrogen) under reducing conditions, transferred to polyvinylidene difluoride membranes and immunoblotted with rabbit anti-phospho-Zap70 Ab (CST), rabbit antiphospho-LAT Ab (Upstate), and/or anti-actin Ab (Santa Cruz).
MS/MS mass spectroscopy -For MS/MS mass spectroscopy to determine sugar nucleotide levels, Jurkat T-cell pellets (20x106 cells) were resuspended in cold 300 ml methanol:water (1:1) solution containing maltose as an internal standard, vortexed for 10 seconds, and then pipetted into tubes containing 600 ml of chloroform:methanol (C:M) (3:2). Maltose (100 pmoles) was added to each sample as internal standard. Samples were vortexed for 1 minute, and then centrifuged at 14,000 rpm for 5 minutes at 4°C. Supernatants were collected, and an equal volume of C:M (1:1) was added, followed by a second extraction. The pooled aqueous fraction containing the hydrophilic metabolite was dried with a speedvac, passed over C18 SepPak in water, dried and stored at -80°C. Prior to injection, the samples were dissolved in 100 ml methanol:water (1:1). The samples were injected at 150 ml/hr, and analyzed on a 4000QTRAP (Mass Spectrometer (SCIEX). The metabolites were identified by their transitions in MS/MS, and quantified using the Analyst Software (Applied Biosystems-SCIEX), which measured the area under the curve for major fragment ion (M2) corresponding to each parent ion (M1). Collision energy (CE), declustering potential (DP) and ion spray voltage (IS) were optimized for each metabolite. UDP-GlcNAc (M1= 605.9, and M2 = 385.0 with setting DP, -40; CE, -38; and IS, -3500) and UDP-Gal (M1= 564.9, and M2 = 323.0 with setting DP, +80; CE, +23; IS, +5500) were measured in negative and positive, respectively. Maltose was measured in negative mode (M1= 341, and M2 = 161 with setting DP, -40; CE, -13; and IS, -4000). Standards for maltose, UDP-GlcNAc and UDP-Gal showed sensitivity to 15 pmoles and linearity to 10 nmoles. Data is reported as UDP-HexNAc and UDP-Hex due to potential inter-conversion of UDP-GlcNAc to UDP-GalNAc and UDP-Gal to UDP-Glc by 4'-epimerase activity, sugar nucleotides not distinguished in M1.
In Vivo GlcNAc Treatment -GlcNAc was administered orally in age and sex-matched PL/J littermate mice by adding GlcNAc to their drinking water at various concentrations. Fresh GlcNAc was given daily for 5 days, with amount consumed approximated by determining the volume remaining after 24h. After 5 days of treatment, harvested splenocytes were stained and analyzed by FACS.
Cytokine ELISA -Supernatant from splenocyte and/or T cell cultures stimulated with MBP and/or anti-CD3ε (2C11, eBioscience) in the presence or absence of GlcNAc and/or SW were tested for IFN-γ, IL-6, and/or IL-4 levels by ELISA. Microtiter plates were coated with 50 µl of anti-IFN-γ (1 µg/ml, clone AN-18; eBioscience), anti-IL-6 (1.5 µg/ml, clone MP5-20F3; eBioscience), or anti-IL-4 (2 µg/ml, clone 11B11; eBioscience) overnight at 4°C. Supernatants were applied at 50 µl/well and incubated for 2 h at room temperature. Captured cytokines were detected using biotinylated anti-IFN-γ (1 µg/ml, clone R4-6A2; eBioscience), anti-IL-6 (1 µg/ml, clone MP5-32C11; eBioscience) or anti-IL-4 (1 µg/ml, clone BVD6-24G2; eBioscience) and detected using Avidin Horse Radish Peroxidase (eBioscience) at 1:500x dilution and o-Phenylenediamine + T cells were purified by negative selection (R&D Systems) and injected i.p. into naïve PL/J Mgat5 +/-recipient mice. Trypan blue exclusion determined <5% dead cells under both culture conditions. Mice were scored daily for clinical signs of EAE over the next 30 days with the observer blinded to treatment conditions. Mice were examined daily for clinical signs of EAE and scored in a blinded fashion as follows: 0, no disease; 1, loss of tail tone; 2, hindlimb weakness; 3, hindlimb paralysis; 4, forelimb weakness or paralysis and hindlimb paralysis; 5, moribund or dead. GlcNAc was administered orally to female NOD mice by adding fresh GlcNAc at a concentration of 250ug/ml to the drinking water every 3 days. Spontaneous diabetes in wildtype NOD mice was diagnosed following two consecutive positive tests for glycosuria of ≥2000 mg/dl by Chemstrip (Accu-chek, Roche) 1 week apart.
RESULTS

T cell thresholds and fractional changes in
β1,6GlcNAc-branching -Conditional or metabolic regulation of T cell activation thresholds could be expected to be sensitive to small incremental changes in N-glycan branching. To test this hypothesis, we compared the agonist sensitivity of primary T cells from Mgat5 2C ). To confirm that small reductions in β1,6GlcNAc-branched N-glycans enhance TCR sensitivity, we treated wild type cells with minimal concentrations of swainsonine (SW). SW is a specific inhibitor of mannosidase II that blocks GlcNAc branching in N-glycans, and is known to enhance T cell proliferation and T H 1 differentiation (23;25). At low levels of anti-CD3 stimulation, partial reductions in β1,6GlcNAc-branched N-glycans by low doses of swainsonine significantly enhance wild type T cell proliferation ( Fig. 2D ) (25;26). Thus, changes in T cell activation thresholds can be readily detected with as little as ~20-25% variations in β1,6GlcNAc-branched N-glycans.
Metabolic flux through the hexosamine pathway regulates β1,6GlcNAc-branched N-glycans in T cells -
The expression of tri-(ie β1,4) and tetra-(ie β1,6) antennary GlcNAc-branched N-glycans in cultured cells is sensitive to changes in the intracellular concentration of UDP-GlcNAc (14;22), which enters the Golgi via UDP-GlcNAc transporters (27). The addition of GlcNAc to cultured cells supplements UDP-GlcNAc pools following uptake by bulk endocytosis, 6-phosphorylation and conversion to UDP-GlcNAc ( Fig. 1) (14;22) . Glucose, glutamine, acetyl-CoA and UTP are metabolites required by the hexosamine pathway for de novo UDP-GlcNAc biosynthesis ( Fig. 1) . TCR activation of mouse T cells increases Mgat5 gene expression (15) , glucose uptake (28), UDP-HexNAc levels (22) and β1,6GlcNAc-branched N-glycans (23) . GlcNAc supplementation of activated T cells further enhances UDP-HexNAc levels, increasing the UDP-HexNAc:UDP-Hex ratio upto ~6 fold (22) . To determine whether hexosmaine metabolite supplementation enhances expression of cell surface galectin ligands (ie N-glycan GlcNAc-branching and poly-N-acetyllactosamine) in resting T cells, cells were titrated with various metabolites until a plateau was reached in L-PHA staining or toxicity was observed. Surface levels of β1,6GlcNAc-branched N-glycans (ie L-PHA staining) and poly-N-acetyllactosamine (indicated by staining with the plant lectin Lycopersicon esculentum agglutinin (LEA)) on non-TCR activated human Jurkat T-cells were increased by supplementing the hexosamine pathway with high glucose, GlcNAc, acetoacetate, glutamine, ammonia or uridine but not with control metabolites mannosamine, galactose, mannose, succinate or pyruvate (Fig. 3, A and B; supplemental Fig. 1, A and B) . Supplementing resting mouse ex vivo splenocytes with GlcNAc, glucose or uridine in vitro significantly raised β1,6GlcNAc-branched N-glycans in CD4 + T cells (Fig. 4A) .
In non-T cells, GlcNAc supplementation also increases tri-antennary structures (22) and these are likely also enhanced in supplemented T cells. MS/MS mass spectroscopy confirmed that GlcNAc, Glucose, and uridine supplements raised intracellular UDPHexNAc levels in non-TCR activated Jurkat T cells (Fig. 3C) . On a per cell basis, UDP-HexNAc levels in Jurkat T cells appear lower than that reported for CHO cells (29); however T cells are smaller and have a markedly higher nuclear to cytoplasmic ratio, making direct comparisons difficult. Co-supplementation of GlcNAc and uridine in resting Jurkat and wildtype mouse T cells were additive and more effective than doubling the GlcNAc concentration ( Fig. 3D; Fig.  4B ). Supplementing the drinking water of Mgat5 Suppression of T cell function and autoimmunity by the hexosamine pathway is dependent on Nglycan GlcNAc-branching -Genetically induced reductions in T cell β1,6GlcNAc-branching weaken the galectin lattice, enhancing agonist induced TCR clustering and signaling, T H 1 differentiation (ie increased IFNγ and reduced IL-4 production), CTLA-4 endocytosis, T cell proliferation and susceptibility to autoimmunity (Fig. 2 , A-C and (15;22;23)). Consequently, metabolic enhancement of N-glycan GlcNAc branching, particularly β1,6GlcNAc-branching, should strengthen the galectin lattice and negatively regulate these phenotypes. Hexosamine supplementation of wild-type resting T cells with GlcNAc inhibited anti-CD3 induced phosphorylation of lck at activating Y 394 and Zap-70 (Fig. 5A) . TCR signal strength regulates expression of the T cell activation marker CD69 as well as production of IFNγ relative to IL-4 (30), and as expected, both are inhibited by hexosamine supplementation (Fig. 5 , B and C, supplemental Fig. 3, A-C) . CTLA-4 retention at the surface of blasting T cells is promoted by TCR signaling mediated increases in hexosamine flux and Golgi processing to β1,6GlcNAc-branched N-glycans (22) . GlcNAc supplementation significantly increases surface levels of CTLA-4 relative to CD28 in T cell blasts (Fig. 5D ), receptors that compete for binding to CD80/86 on antigen presenting cells to negatively and positively regulate growth arrest, respectively (31). Tracking cell division of purified T cells using CFSE labeling demonstrates that hexosamine supplementation inhibits T cell proliferation without inducing cellular toxicity as measured by 7-AAD ( Fig. 5E; supplemental Fig. 3, D-F) . Very importantly, all observed effects of hexosamine supplementation on T cell function are dependent on N-glycans, as they could be reversed by blocking N-glycan GlcNAc branching beyond mono-antennary with SW and/or the mannosidase I inhibitor deoxymannojirimycin (DMN, Fig. 1 Fig. 3 , B, C, E, and F). These data demonstrate that hexosamine supplementation controls three temporally distinct autoimmune regulatory phenotypes, namely T cell activation thresholds, T H 1 differentiation and CTLA-4 endocytosis, by enhancing GlcNAc branching in N-glycans.
Next, we determined whether hexosamine induced changes in GlcNAc-branched N-glycans suppresses T cell mediated autoimmunity. The MS model EAE may be induced by adoptive transfer of myelin antigen specific T cells into naïve mice, leading to inflammatory demyelination of axons and progressive motor weakness. Splenocytes from myelin basic protein (MBP) immunized wild-type PL/J mice were re-stimulated in vitro with MBP in the presence or absence of GlcNAc, then transferred to naïve mice for induction of EAE. Re-stimulation in the presence of GlcNAc increased β1,6GlcNAc-branched N-glycans and poly-N-acetyllactosamine expression and inhibited production of the T H 1 cytokine IFN-γ while promoting secretion of the T H 2 inducing/T H 1 inhibitory cytokine IL-6 (Fig. 6, A and B) (32). After adoptive transfer of the T cells into naïve PL/J mice, mice receiving the GlcNAcsupplemented cells showed dramatically reduced incidence and severity of EAE compared to mice given untreated cells (Fig. 6C) .
To determine whether oral GlcNAc supplementation inhibits spontaneous autoimmunity, we supplemented the drinking water of female NOD mice at 250µg/ml, a concentration that maximally raises β1,6GlcNAc-branched N-glycans in CD4 + T cells in vivo (Fig.  4C) . GlcNAc supplementation starting between the 5 th and 6 th week of age significantly reduced development of autoimmune diabetes (Fig. 6D) . Insulitis begins at 3-4 weeks of age in NOD mice (11) , suggesting initiation of GlcNAc supplementation prior to insulitis may further reduce development of diabetes.
Others have demonstrated that in vitro and/or in vivo supplementation of mice with Glucosamine (GlcN) inhibits T cell activation, T H 1 responses as well as graft rejection and EAE; but the mechanism is unknown (12;13). GlcN enters the hexosamine pathway following 6-phosphorylation (Fig. 1) . Our data demonstrates that GlcN also increases β1,6GlcNAc-branching in T cells, with maximal changes occurring at ~100-150 µM (supplemental Fig. S1C ), the same concentration that others have found inhibit proliferation and T H 1 differentiation (13) . Taken together, these data indicate key metabolites shared by hexosamine, glycolysis, lipid (free fatty acids to acetyl-CoA), amino acid (ie ammonia/glutamine) and nucleotide metabolism conditionally regulate thresholds for T cell function and autoimmunity by altering GlcNAc-branching in N-glycans.
DISCUSSION
GlcNAc-branching in N-glycans titrates binding to galectins, forming a molecular lattice at the cell surface that negatively regulates TCR sensitivity, T H 1 differentiation, CTLA-4 endocytosis, and the threshold to autoimmunity (15;22;23 ). Here we demonstrate that T cell function and autoimmunity are regulated by the nutrient environment and metabolite supply to the hexosamine pathway in a N-glycan GlcNAc-branching-dependent manner. This implies that genetic contributions to intracellular metabolic homeostasis, coupled with the nutrient environment, regulate GlcNAcbranching in N-glycans, and thereby autoimmune susceptibility. Autoimmunity is a complex trait disease, where genetic susceptibility is modulated by the environment via unclear mechanisms. In this regard, metabolic regulation of GlcNAcbranching provides an environmental mechanism to influence genetic predisposition to autoimmunity (Fig. 7) .
GlcNAc and GlcN supplement the hexosamine pathway (Fig. 1) , increase β1,6GlcNAc-branched N-glycans and inhibit T cell function and autoimmunity (Fig. 3B, 4A , 5A-E, 6A-C and supplemental Fig. S1C ) (12;13) . GlcN enters cells via glucose transporters, allowing a ~200-400 fold reduction in effective concentration relative to GlcNAc, which is taken up by bulk endocytosis. However, maximal increases in β1,6GlcNAc-branched N-glycans are ~2-4 fold greater with GlcNAc than GlcN.
Moreover, increasing concentrations of GlcN (>200µM), unlike GlcNAc, reduces β1,6GlcNAc-branched N-glycans. GlcN-6-P but not GlcNAc-6-P is a potent inhibitor of glutamine-fructose-6-P aminotransferase (GFAT), the rate-limiting enzyme shunting fructose-6-phosphate into the hexosamine pathway (33). GlcN-6-P may also exit the hexosamine pathway to enter glycolysis following de-amination by glucosamine-6-phosphate deaminase (GNPD) (Fig.  1) . These data suggest GlcNAc functions as a better inducer of β1,6GlcNAc-branching as GFAT product inhibition and/or enhanced GNPD activity may limit the effectiveness of GlcN. In this regard, GlcNAc is predicted to be a superior therapeutic agent for prevention and/or treatment of human autoimmunity. Indeed, 8 of 12 children with severe treatment-resistant inflammatory bowel disease had significant clinical improvement following ~2 years of treatment with 3-6g/day of oral GlcNAc (34). Assuming a weight of 40-50kg for these children, which was not reported in the study, the dose used is ~60-150mg/kg/day, similar to the 20-160mg/kg/day dose that maximally raises T cell β1,6GlcNAc branching and inhibits autoimmune diabetes in mice. No significant adverse effects were noted over ~2 yrs of treatment, suggesting GlcNAc therapy is likely to be a safe therapeutic approach in humans. In addition to the N-glycan GlcNAc transferases, UDP-GlcNAc is a sugar-nucleotide donor for the Golgi O-glycan pathway (35) and cytoplasmic OGlcNAc transferase (36). UDP-GlcNAc may also be converted to UDP-GalNAc, the sugarnucleotide utilized by GalNAc transferases to initiate O-glycosylation at Ser/Thr residues. Our data do not exclude metabolic induced changes in these or other pathways requiring UDP-GlcNAc or UDP-GalNAc. However, the N-glycan pathwayspecific inhibitor SW reverses all observed effects of GlcNAc supplementation on T-cell function ( Fig. 2D; Fig. 5, A-E; supplemental Fig. 3, B, C, E,  and F) . Similarly, GlcNAc dependent inhibition of receptor endocytosis is reversed by mutation of N-glycosylation sites (ie N-X-S/T) and by knockout of Mgat1 (22) .
Thus, metabolic regulation of GlcNAc-branched N-glycans is necessary and sufficient to produce the observed autoimmune inhibitory T cell phenotypes (ie T cell activation thresholds, T H 1 differentiation and CTLA-4 surface expression), identifying Nglycans as a major target of hexosamine mediated inhibition of autoimmunity.
β1,6GlcNAc-branched N-glycans are present on β1 integrins and negatively regulate cell adhesion and promote tumor cell motility (19;24;37). Substratum and cell-cell adhesion regulates several aspects of T cell activation and migration. Antibodies that disrupt binding of T cellassociated α 4 β 1 integrin to Vascular Cell Adhesion Molecule -1 (VCAM-1) on activated endothelium negatively regulates EAE and MS by blocking T cell recruitment to the CNS (38;39). β1,6 GlcNAcbranching in β1 integrins negatively regulates cell adhesion (24;37;40) including inhibition of T cell binding to VCAM-1 in vitro (M. Demetriou, unpublished data), which may limit T cell recruitment to the CNS in vivo. Mgat5-deficient macrophages have decreased motility and phagocytosis (19) , a phenotype that may promote autoimmunity by inhibiting clearance of apoptotic cells (41).
Mutations in genes of apparently distinct pathways for TCR signal strength (42-44), T H 1 differentiation (45) and CTLA-4 expression (46) promote T cell mediated autoimmunity. However, targets of N-glycan GlcANc branching include TCR, CTLA-4 and other surface glycoproteins (15;22;23) , and taken with our results, N-glycan processing appears to serve as an intermediate in the conditional regulation of the cellular immune system. The hexosamine/Golgi processing pathways regulate at least three temporally distinct T cell phenotypes (activation, T H differentiation, arrest) (15;22;23) . This suggests that the hexosamine and Golgi pathways have co-evolved with the larger regulatory network that controls the cellular immune system. With a better understanding of the hexosamine pathway and its regulation of the immune system in vivo, metabolic therapy of human autoimmune disease may prove to be a useful intervention (47 The authors declare that they have no competing financial interests. Fig. 1 . Regulation of GlcNAc-branched N-glycan biosynthesis by the Hexosamine and N-glycan pathways. UDP-GlcNAc is required by the N-acetylglucosaminyltransferases Mgat1, 2, 3, 4 & 5 and iGnT. Size of the arrows for Mgat1, 2, 4 and 5 depicts relative affinity for UDP-GlcNAc, with K m below arrows. Cytosolic UDP-GlcNAc enters the Golgi via anti-porter exchange with Golgi UMP, a reaction product of the N-acetylglucosaminyltransferases. Galectins bind N-acetyllactosamine, with avidity increasing in proportion to the number N-acetyllactosamine units (ie GlcNAc branching). β1,6GlcNAc-branching by Mgat5 promotes poly-N-acetyllactosamine production, further enhancing avidity for galectins. DMN, deoxymannojirimycin; SW, swainsonine; GI, glucosidase I; GII, glucosidase II; MI, mannosidase I; MIIx, mannosidase IIx; GalT3, galactosyltransferase3. A bypass pathway involving Mgat1 activity prior to mannosidase II is not shown. FACS (A,B,D) or lysed and analyzed by MS/MS mass spectroscopy for sugar-nucleotide expression (C). Green, blue and red lines in (B) refer to altered glucose concentration in the culture media as indicated; all others were cultured in 10 mM glucose. UDP-HexNAc and UDP-Hex levels in non-supplemented cells were below the detection level of our assay. Detection via HPLC indicates GlcNAc supplementation increases the UDP-HexNAc:UDP-Hex ratio upto ~6 fold in TCR activated mouse T cells (22) . Error bars are present in (A,B,D) and represent mean ± standard error of triplicate staining. P values in D are by ANOVA and the Newman-Keuls multiple comparison test with non-supplemented cells or as indicated. *p<0.05, **p<0.01, ***p<0.001 . Error bars indicate mean ± standard error of duplicate samples and P values determined by Student t test. IL-4 was below ~30 pg/ml, the detection limit of our ELISA. C, 3.6 million CD3 + T cells were injected into naïve Mgat5 +/-mice (n=7 for each condition) and scored for signs of EAE daily for 30 days. D, The drinking water of female NOD mice was supplemented with (n=15) or without (n=15) 250µg/ml GlcNAc starting between 5-6 weeks of age. Mice were assessed for glycosuria weekly, with diagnosis of diabetes made after two consecutive positive tests of ≥2000 mg/dl glucose by Chemstrip 1 week apart. P values for EAE and diabetes incidence was determined by Fisher's exact test. P values for EAE mean score, disease duration and highest clinical score were determined by the Mann-Whitney test. 
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